F 0401

Drug Profile

F 0401

Alternative Names: D 31 D

Latest Information Update: 29 Feb 2000

Price : $50

At a glance

  • Originator UCB Japan
  • Class Antihypertensives; Antiplatelets; Vasodilators
  • Mechanism of Action Calcium channel antagonists; Platelet activating factor inhibitors; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 29 Feb 2000 Fujirebio has been acquired by UCB
  • 27 Apr 1998 Profile reviewed
  • 06 Jan 1997 Discontinued-Preclinical for Stroke in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top